This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
NGP Paper
NGP Paper - The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial
The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial

Publishing date: September 2021

Author(s): Boel Bengtsson (1), Christina Lindén (2), Anders Heijl (1), Sabina Andersson-Geimer (1), Johan Aspberg (1), Gauti Jóhannesson (2,3)

1 Department of Clinical Scien,ces in Malmö, Ophthalmology, Lund University, Lund, Sweden.
2 Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.
3 Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.

PURPOSE: The aim of the study was to determine the perimetric rate of glaucoma progression in the ongoing Glaucoma Intensive Treatment Study (GITS) after 3 years of follow-up.

DESIGN: This is a randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma (OAG).

PARTICIPANTS: The participants of this study were treatment-naive patients with newly diagnosed OAG, aged 46-78 years, with early to moderate glaucomatous visual field loss scheduled to be followed for 5 years within the study.

METHODS: Patients were randomized to initial treatment with either topical monotherapy or with an intensive approach using drugs from three different classes, plus 360° laser trabeculoplasty. Changes in treatment were allowed. Standard automated perimetry and tonometry were performed and side-effects documented. All results are presented using intention-to-treat analysis.

RESULTS: A total of 242 patients were randomized. After 3 years of follow-up, eight patients were lost to follow-up, six of whom were deceased. The median untreated baseline intraocular pressure (IOP) was 24 mmHg in both arms. The median IOP was almost constant over the 3 years of follow-up: ≈17 mmHg in the mono-arm and ≈14 mmHg in the multi-treatment arm. Treatment was intensified in 42% of the mono-treated patients and in 7% of the multi-treated patients. Treatment was reduced in 13% of the multi-treated patients. The median perimetric rate of progression was -0.5%/year in the mono-treated group and -0.1%/year in the multi-treated group (p = 0.03).

CONCLUSION: The rate of disease progression was significantly slower in the multi-treated patients than in the mono-treated patients. Further follow-up will show whether this difference is sustained over time.

© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

PMID: 34327833 DOI: 10.1111/aos.14978

Keywords: RCT; drug trial; glaucoma; progression; visual field

NGP Papers manager: Carlo Cutolo

back to top